Richard S. Lindahl - Mar 2, 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Chief Financial Officer
Signature
/s/ Jennifer Lynn Fox, Attorney-in-fact
Stock symbol
EBS
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 06:36 PM
Previous filing
Mar 2, 2023
Next filing
Apr 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +6.15K +7.63% $0.00 86.8K Mar 2, 2023 Direct F1, F2
transaction EBS Common Stock Award $0 +12.3K +14.17% $0.00 99.1K Mar 2, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Options (Right to Buy) Award $0 +12.3K +15.24% $0.00 93K Mar 2, 2023 Common Stock 12.3K $12.06 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2 Represents the corrected number of securities owned due to a computational error on prior Form-4.
F3 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F4 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.